Matthew R B Evans
Overview
Explore the profile of Matthew R B Evans including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
169
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Evans M, Salhab H, Sinclair C, Shah S, Hanna M, Yousry T, et al.
Ann Clin Transl Neurol
. 2025 Feb;
PMID: 39957630
Objective: We measured clinical and quantitative MRI outcome measures in CMT1A to assess long-term responsiveness, establish longitudinal validity and assess MRI as a bridging biomarker. Methods: Twenty patients with CMT1A...
2.
Morrow J, Shah S, Cristiano L, Evans M, Doherty C, Alnaemi T, et al.
Eur Radiol Exp
. 2024 Jul;
8(1):85.
PMID: 39060637
Background: Magnetic resonance imaging (MRI) quantification of intramuscular fat accumulation is a responsive biomarker in neuromuscular diseases. Despite emergence of automated methods, manual muscle segmentation remains an essential foundation. We...
3.
Cheng M, Murphy P, Hart N, Evans M, Spillane J, Howard R
Neurol Clin Pract
. 2021 May;
11(1):18-24.
PMID: 33968468
Background: Recovery from Guillain-Barré syndrome (GBS) may be protracted, and patients may need prolonged ventilatory support. We present clinical data from a tertiary referral weaning center managing patients with GBS...
4.
Kugathasan U, Evans M, Morrow J, Sinclair C, Thornton J, Yousry T, et al.
J Neurol Neurosurg Psychiatry
. 2019 Apr;
90(8):895-906.
PMID: 30995999
Objectives: Hereditary sensory neuropathy type 1 (HSN1) is a rare, slowly progressive neuropathy causing profound sensory deficits and often severe motor loss. L-serine supplementation is a possible candidate therapy but...
5.
Morrow J, Evans M, Grider T, Sinclair C, Thedens D, Shah S, et al.
Neurology
. 2018 Aug;
91(12):e1125-e1129.
PMID: 30120135
Objective: To translate the quantitative MRC Centre MRI protocol in Charcot-Marie-Tooth disease type 1A (CMT1A) to a second site; validate its responsiveness in an independent cohort; and test the benefit...
6.
Bishop C, Ricotti V, Sinclair C, Evans M, Butler J, Morrow J, et al.
Front Neurol
. 2018 Feb;
9:9.
PMID: 29434565
Subjects with Duchenne Muscular Dystrophy (DMD) suffer from progressive muscle damage leading to diaphragmatic weakness that ultimately requires ventilation. Emerging treatments have generated interest in better characterizing the natural history...
7.
Evans M, White P, Cowley P, Werring D
Pract Neurol
. 2017 Jun;
17(4):252-265.
PMID: 28647705
Rapid, safe and effective arterial recanalisation to restore blood flow and improve functional outcome remains the primary goal of hyperacute ischaemic stroke management. The benefit of intravenous thrombolysis with recombinant...
8.
Sinclair C, Morrow J, Janiczek R, Evans M, Rawah E, Shah S, et al.
NMR Biomed
. 2016 Nov;
29(12):1800-1812.
PMID: 27809381
Quantifying muscle water T (T -water) independently of intramuscular fat content is essential in establishing T -water as an outcome measure for imminent new therapy trials in neuromuscular diseases. IDEAL-CPMG...
9.
Ricotti V, Evans M, Sinclair C, Butler J, Ridout D, Hogrel J, et al.
PLoS One
. 2016 Sep;
11(9):e0162542.
PMID: 27649492
Objective: A number of promising experimental therapies for Duchenne muscular dystrophy (DMD) are emerging. Clinical trials currently rely on invasive biopsies or motivation-dependent functional tests to assess outcome. Quantitative muscle...
10.
Evans M, Weeks R
Pract Neurol
. 2016 Jun;
16(6):484-487.
PMID: 27354565
The anatomical localisation of brainstem syndromes is the domain of the clinical neurologist, though MRI has made an encyclopaedic knowledge of neuroanatomy less crucial. Isolated pontine syndromes comprise ∼20% of...